Skip to main content

drug costs Archives

Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs

Feb. 9, 2023—Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.

Read more


Researcher’s decade of analyzing the price of drugs leads to big reforms

Nov. 3, 2022—Vanderbilt's Stacie Dusetzina, PhD, and several colleagues were able to reflect recently on the South Lawn of the White House about how their contributions through research and data informed the provisions in the Inflation Reduction Act that will save older Americans on Medicare tens of thousands of dollars in out-of-pocket costs each year.

Read more


New study illustrates how much it would cost for cancer drugs covered under Medicare Part D

May. 10, 2022—A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.

Read more


Study finds sexual minority communities disproportionately engage in behaviors to reduce medication costs

Jan. 6, 2022—Vanderbilt research finds that individuals from sexual minority populations, including members of the lesbian, gay, bisexual and queer communities, are more likely than heterosexual individuals to engage in behaviors to reduce medication costs.

Read more


Study to explore how rising medication costs impact elderly

Aug. 9, 2018—As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.

Read more


Study finds generic options offer limited savings for expensive drugs

May. 9, 2018—Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more